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Abstract: Background and objectives: Autism spectrum disorder (ASD) is a neurodevelopmental
disorder characterized by impaired communication, social interaction disorder, and repetitive
behavior. Dysbiotic gut microbiota (GM) could be a contributing factor to the appearance of ASD,
as gastrointestinal (GI) symptoms are comorbidities frequently reported in ASD. As there is a lack
of reviews about the role played by GM in the GI symptoms of ASD, this work aimed to carry out
a systematic review of current studies comparing the GM of children with ASD and GI symptoms
with those of healthy controls in the last six years. Materials and Methods: The systematic review was
performed following the PRISMA guidelines. The databases chosen were Web of Science, Scopus,
PubMed, and PsycINFO, and the keywords were (gut* OR intestine* OR bowel* OR gastrointestinal*)
AND (microbiota* OR microflora* OR bacteria* OR microbiome* OR flora* OR bacterial* OR bacteria*
OR microorganism* OR feces* OR stool*) AND (autistic* OR autism* OR ASD*). Results: A total of 16
articles were included. Ten articles performed correlations analysis between GI symptoms and ASD.
Among those 10 articles, 7 found differences between the GI symptoms present in children with ASD
and healthy controls. The most common GI symptom was constipation. Among the seven articles
that found differences, three performed correlations analysis between GI symptoms and gut microbe
abundance. Candida, Prevotella, Streptococcus, and Veillonella showed higher and lower abundance,
respectively, in children with ASD and GI symptoms in more than one article. Bacteroidetes, Firmicutes,
Actinomyces, Dorea, Lactobacillus, Faecalibacterium prausnitzii, and Bacteroidetes/Firmicutes ratios showed
abundance discrepancies. Conclusions: It is still too early to draw a conclusion about the gut microbes
involved in GI symptoms of ASD. Future research should consider the relationship between ASD
behavior, GM, and GI symptoms in a multidisciplinary way and homogenize sample characteristics.
Keywords: autism; children; gastrointestinal symptoms; gut microbiota; systematic review
1. Introduction
Autism or autism spectrum disorder (ASD) is defined in the Diagnostic and Statistical Manual
for Mental Disorders (Fifth Edition (DSM-5)) as a heterogeneous group of neurodevelopmental
disorders featuring the three main characteristics of impaired communication, social interaction
disorder, and repetitive behavior [1]. Autism includes Kanner’s autism [2], Asperger’s syndrome [3],
and pervasive developmental disorder not otherwise specified (PDD-NOS), and is characterized by
persistent deficits in social communication interaction and restricted–repetitive patterns of behavior,
interests, or activities [1]. It is worth mentioning that people without neurological, medical, or
psychiatric diagnoses are defined as neurotypical in the autism community [4].
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Autism originally affected one in 10,000 in the 1950s, but now affects one in every 58 people in USA
and around one in 30 in Korea, being more prevalent in men (4:1) [5], and possibly in recent immigrant
populations (i.e., Somali expatriates in Sweden [6]), suggesting some link with industrialization. In this
sense, there is a need for the scientific community to discover the root causes of ASD and the complex
interactions between genetic, epigenetic, immunological, neurological, and environmental factors that
might be contributing to the development and expression of ASD in sensitive populations [5,7].
People with ASD develop several comorbidities, including gut-related comorbidities such as
gastrointestinal (GI) symptoms, increased permeability of the epithelial barrier in the gut, decreased
expression of brush border disaccharidases in the gut epithelium, and altered gut microbiota (GM)
composition; brain-related comorbidities such as altered expression of tight junction proteins in the
blood–brain barrier and increased amounts of activated microglial cells; and other comorbidities such
as mitochondrial dysfunction, fragile X syndrome, Rett syndrome, and tuberous sclerosis, and altered
metabolite profiles in urine and blood [8].
Among the comorbidities developed by people with ASD, GI symptoms such as diarrhea,
constipation, commutative diarrhea/constipation, abdominal pain, vomiting, reflux, or bloating are
quite common, and they are correlated with the severity of the neurobehavioral disorder [9]. In this sense,
people with ASD with GI symptoms exhibit more anxiety problems and other somatic complaints,
together with less social interaction than ASD people without GI symptoms [8]. For example,
Marler et al. [10] reported that constipation was found to be the most common GI symptom in ASD
people, and that there is a connection between rigid–compulsive behavior and the occurrence of
constipation. In addition, people with ASD and GI problems also show more tantrums, aggressive
behavior, self-injury, and sleep disturbances, which might be an expression of abdominal discomfort [8].
The etiology of GI symptoms in ASD remains unknown, and everything seems to indicate that
it is a combination of associated factors [9,11]. However, GI symptoms appear to be due, in part, to
dysbiotic GM. In this sense, there is enough scientific evidence regarding the relationship between a
dysbiotic GM and the development of diverse chronic diseases such as asthma, intestinal inflammation
associated with the pathogenesis of obesity, type 2 diabetes mellitus [12], and other neurodevelopmental
disorders [13].
The GM encompasses the set of bacteria that inhabit the (GI) tract. These bacteria have a dynamic
symbiotic relationship that is both commensal and mutual throughout the host lifecycle [14]. At present,
the microbiota–gut–brain axis is an explanatory model that attempts to relate the symptoms of ASD
to the findings in neuroscience and bacteriology; it is defined as a bidirectional communication
system between the neuronal, immune, endocrine, and metabolic pathways, but still requires a better
understanding [15].
As discussed before, as GI symptoms can be related to dysbiotic GM, the use of pre/probiotics
and microbiota transfer therapy (MTT) as therapeutic tools to treat people with ASD have been
gaining greater interest in recent years, as they may help to restore normal GM, reduce inflammation,
restore epithelial barrier function, and possibly improve some behavioral symptoms associated with
ASD [16–18]. For example, Shaaban et al. [19] observed beneficial effects on both behavioral and GI
manifestations in Egyptian ASD children with GI symptoms after administering Lactobacillus acidophilus,
Lactobacillus rhamnosus, and Bifidobacteria longum, and Kang et al. [18] reported improvements in the
microbiome and both GI and ASD symptoms in American ASD children with GI symptoms after
MTT. These improvements were sustained at least 8 weeks after treatment. In addition, it has been
reported that diet also has a strong correlation with GI symptoms in children with ASD [20], and GM
appears to be affected by diet and has a modulatory role in several disease states. For example, besides
pre/probiotics, dietary polyphenols, which are often indigestible, may also positively influence GM [21].
In one case, Sprague Dawley rats with hepatic steatosis who were administered a high-fat diet were
later given curcumin, which not only restored intestinal barrier integrity (increasing the expression of
tight junction proteins ZO-1 and occluding), but also markedly altered the overall composition of the
GM towards that of lean rats maintained on a normal diet [22]. Of note, a strong correlation between
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GI symptoms and diet problems in ASD children, especially idiosyncratic feeding behavior, has been
also reported, and ASD children suffering from multiple GI symptoms tend to be those who also have
dietary problems [23].
Traditionally, characterization of GM has been carried out using culture-dependent techniques.
One of the great limitations of these techniques is that it is impossible to ensure that the phenotypic
behavior of a microorganism in the laboratory is identical to its behavior in vivo, due in part
to the processes of metabolic symbiosis between microorganisms. In addition, the number of
microorganisms that can be characterized with this technique is limited [24]. However, the emergence
and rapid development of culture-independent or molecular techniques has made culture-dependent
techniques nearly obsolete, and the characterization of GM is currently largely carried out using
culture-independent techniques, as they allow scientists to easily identify a large proportion of bacterial
diversity and provide rapid results [25,26]. This has led to many studies that compare the diversity
of the GM of ASD children with healthy controls [27–31], of which a bibliographic review can be
carried out. In this sense, several bibliographic reviews about GM and ASD can be found in the
scientific literature. For example, Hughes et al. [32] and Liu et al. [33] studied the dysbiosis of GM in
ASD, and Andreo-Martínez et al. [34] studied the gut microbes belonging to the Fungi kingdom in
people with ASD. In addition, there have been few studies that have analyzed the correlation between
GM composition and GI symptoms in people with ASD. For example, in a meta-analysis about GI
symptoms in ASD [9], performed on studies published until 2012, there was only one study [35]
which reported that GI symptoms in people with ASD were correlated with high levels of Clostridium
(p = 0.001). However, to the author’s best knowledge, there have been no bibliographic reviews that
have attempted to relate the gut microbes involved in the GI symptoms of people with ASD. Therefore,
the aim of the present work was to carry out a systematic review on the studies that have compared the
GM of people with ASD and GI symptoms with those of healthy controls, continuing the meta-analysis
line of McElhanon, McCracken, Karpen, and Sharp [9], during the last six years, to try to find some
bacterial abundance patterns and to identify future research strategies.
2. Materials and Methods
The design of the present systematic review was performed following the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [36]. This systematic approach
under the PRISMA perspective covers the developments in the field of the GM of people with ASD
and GI symptoms by providing critical analysis of key parameters, such as the role that gut microbes
play in the GI symptoms of people with ASD, and gut microbe abundance of people with ASD with
GI symptoms.
The bibliographic search was performed for works published between 2012 and February 2019,
and the four comprehensive databases chosen to carry out the bibliographic search were: Web of
Science, Scopus, PubMed, and PsycINFO. The Boolean strings entered to carry out the search were:
(gut* OR intestine* OR bowel* OR gastrointestinal*) AND (microbiota* OR microflora* OR bacteria*
OR microbiome* OR flora* OR bacterial* OR bacteria* OR microorganism* OR feces* OR stool*) AND
(autistic* OR autism* OR ASD*), and the searches included works published in all language. Scopus
search options were: title, abstract, and keywords; Web of Science search option was “theme,” while for
PsycINFO and PubMed, the search option selected was all fields.
The inclusion criteria were: (1) articles with human populations; (2) articles published from 2012
to February 2019; and (3) articles comparing the GM of children with ASD and GI symptoms with those
of control groups. The exclusion criteria were: (1) descriptive and systematic reviews; (2) books and
book chapters; (3) editorial material, letters to the editor, shorts reports, and proceedings of conferences;
(4) animal model and in vitro articles; (5) other diseases; (6) articles studying only metabolites in blood,
plasma, or urine; and (7) articles published in a language other than English.
The 1540 works obtained by the four databases were passed through EndNote X7 software
(Thomson Reuters, New York, USA) to delete possible duplicated works. According to the PRISMA
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methodology, A.E.M.-G. and P.A.-M. formed the review team and independently screened titles,
abstracts, and full texts of the works for potential inclusion. These two authors evaluated them
according to the inclusion or exclusion criteria, and disagreements on whether a given reference should
be included or not were resolved through discussion. In addition, the reference lists of the selected
works were also examined in search of potentially relevant papers, not finding any additional article
in this step. It is noteworthy that some of the works could be included in more than one elimination
group, but the final criteria were agreed by the review team. Finally, a total of 16 articles were found to
be eligible for the present systematic review and they are shown in Table 1. The risk of bias for each
included study was evaluated using the Methods Guide for Comparative Effectiveness Reviews [37].
The forms of bias considered are presented in Table 2.
Figure 1 shows the process of identifying articles for inclusion in the present systematic review.
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Table 1. Characteristics of the selected studies on gut microbiota and children with ASD and GI symptoms.
Reference
Subjects Method Findings Limitations
Experimental Group Control Group Bacteria Correlation
[38]
ASD (n = 23) divided into ASD
w GI symptoms (12/23) and
ASD w/o GI symptoms (11/23)
Range Age 3–10 y (15/23 aged
3–5 y;
6/23 aged 6–7 y;
2/23 aged 8–10 y)
All males
HC w GI symptoms (n = 9)
Range Age 3–10 y (7/9 aged 3–5
y;
1/9 aged 6–7 y;
1/9 aged 8–10 y).
All males
Pyrosequencing of the 16S rRNA gene
pan-bacterial (V2 region) on ileal and
ceca mucosal biopsy samples
PCR-based detection of Sutterella 16S
rRNA gene sequences (V6–V8 region
and C4–V8 region) on ileal and ceca
mucosal biopsy samples
Sutterella ↑ in ASD w GI symptoms vs.
HC w GI symptoms (ilea p = 0.022/ceca
p = 0.037)
No correlations between GM and GI symptoms
were studies
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
[39]
ASD (n = 51) divided into ASD
w GI symptoms (28/51) and
ASD w/o GI symptoms (23/51)
Age 2–12 y
42 males
9 females
NT Sib (n = 53)
Age 2–12 y
19 males
34 females
Pyrosequencing (bTEFAP) of the 16S
rRNA gene bacterial (V1–V3 regions) on
fecal samples
No difference in microbiome between
total ASD vs. NT Sib.
No difference regarding severity ASD in
the bacterial composition.
No difference regarding GI symptoms
dysfunction in the bacterial composition
(No differences within the ASD group
compared to both with and without GI
symptoms groups)
No metabolites were studied
Was not indicated
whether the ASD
subjects had
intellectual disability
[27]
ASD w GI symptoms (n = 20)
Age 3–16 y
18 males
2 females
NT w GI symptoms (n = 20)
Age 3–16 y
17 males
3 females
Pyrosequencing (bTEFAP) of the 16S
rRNA gene bacterial (V2–V3 regions) on
fecal samples
Quantitative real-time PCR for Prevotella
Prevotella (p = 0.04), Coprococcus (p ≤
0.06) and unclassified Veillonellaceae
(p = 0.04) ↓ in ASD vs. NT.
Microbial changes were more closely
linked to the presence of autistic
symptoms rather than to the severity of
GI symptoms and specific
diet/supplement regimens
No correlations between GM and GI symptoms
were studies
Was not indicated
whether the ASD
subjects had
intellectual disability
[40]
ASD (n = 23) w or w/o GI
symptoms
Age 3–18 y
Unrevealed sex
HC (n = 9) and
NT sib (n = 22) w or w/o GI
symptoms
Age 3–18 y
Unrevealed sex
qPCR for Sutterella, Ruminococcus torques
and R. gnavus on fecal samples.
Sutterella ↑ (p = 0.044) in ASD vs. NT Sib.
Sutterella ↑ (p = 0.05) in ASD vs. HC.
Sutterella ↑ (p = 0.047) in NT Sib vs. HC.
Ruminococcus gnavus ↑ (p = 0.046) in NT
Sib vs. HC.
Ruminococcus torques ↑ (p = 0.008) in
ASD w GI symptoms (n = 9) vs. ASD
w/o GI symptoms (n = 14).
No correlations between GM and GI symptoms
were studies
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
[41]
ASD (n = 59) divided into ASD
w GI symptoms (25/59) and
ASD w/o GI symptoms (34/59)
Age 7–14 y
52 males
7 females
NT Sib (n = 44)
divided into NT Sib w GI
symptoms (13/44) and NT Sib
w/o GI symptoms (31/44)
Age 7–14 y
21 males
23 females
qPCR for total bacteria, Sutterella
subgroup, Bacteroidetes subgroup,
Prevotella, C. coccoides-E. rectales
subgroup, Faecalibacterium prausnitzii
and Escherichia coli subgroup on fecal
samples
Sequencing of the 16S rRNA gene
bacterial (V1–V2 and V1–V3 regions) on
fecal samples
No difference between total ASD vs NT
Sib in bacterial frequency.
Increased prevalence of functional
constipation GI symptoms in ASD
children compared to NT siblings
Increased prevalence of functional constipation
GI symptoms in ASD children compared to NT
siblings.
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
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Table 1. Cont.
Reference
Subjects Method Findings Limitations
Experimental Group Control Group Bacteria Correlation
[31]
ASD (n = 10) divided into ASD
w GI symptoms (9/10) and
ASD w/o GI symptoms (1/10)
Age 2–9, 9 males and
1 female
Sib (n = 9) divided into Sib w
GI symptoms (7/9) and
Sib w/o GI symptoms (2/9)
Age 5–17,
7 males and
3 females
HC (n = 10) divided into HC w
GI symptoms (6/10) and
HC w/o GI symptoms (4/10)
Age 2–11, 10 males
qPCR for Bacteroidetes, Firmicutes,
Bifidobacterium, Lactobacillus, Clostridium
cluster 1, S. thermophiles, Desulfovibrio on
fecal samples
Bacteroidetes/Firmicutes ratio↓ in ASD vs.
HC (p < 0.05); ↓ Sib vs. ASD (p < 0.05); ↓
Sib vs. HC (p < 0.05)
Firmicutes ↑ in Sib vs. HC
Lactobacillus ↑ in ASD vs. HC (p < 0.05)
Bifidobacterium ↑ in ASD vs. Sib (p < 0.05)
Desulfovibrio with ASD severity in the ADI
restricted/repetitive behavior subscale score.
There is a correlation of the autism severity with
the severity of GI dysfunction. (p = 0.01)
No correlation of GI symptoms and Desulfovibrio
abundance.
Was not indicated
whether the ASD
subjects had
intellectual disability
[42]
ASD (n = 40) divided into
severe ASD (36/40) and
moderately severe ASD (4/40)
5 constipated
29 non-constipated
Average age 11.1 ± 6.8
31 males
9 females
NT (n = 40)
11 constipated
29 non-constipated
Average age 9.2 ± 7.9
28 males
12 females
Pyrosequencing of the 16S rRNA gene
bacterial (V3–V5 regions) and the
internal transcribed spacer (ITS) for
fungal (ITS1 rDNA region) on fecal
samples
Firmicutes/Bacteroidetes ratio↑,
Bacteroidetes ↓, Veillonella ↓, Alistipes ↓,
Bilophila↓, Dialister↓, Parabacteroides↓ in
ASD vs. NT (p < 0.005)
Lactobacillus ↑, Dorea ↑, Corynebacterium
↑, Collinsella ↑, Candida ↑ in ASD vs. NT
(p < 0.001)
Escherichia/Shigella and cluster XVIII with GI
symptoms or constipation (p < 0.05)
Was not indicated
whether the ASD
subjects had
intellectual disability
[30]
Severe ASD (n = 47) w/o or w
GI symptoms
Average age 6 ± 2.8 y
40 males
7 females
HC (n = 33) w/o or w GI
symptoms
Average age 7.3 ± 3.1 y
24 males
9 females
Examination and culture of fecal
samples:
(a) morphological examination,
(b) microscopic examination staining,
(c) search for toxins a/b of Clostridium
difficilis,
(d) bacterial/yeast culture and
(e) identification of bacteria and yeast
colonies by VITEK 2 microbial
identification system
Candida aggressive form
(pseudo-hyphae presenting)
Candida ↑ in ASD vs. HC (p = 8.67 ×
10−6)
Lactobacillus ↓ in ASD vs. HC
(p = 7.28x10−4)
Clostridium ↓ in ASD vs. HC (p = 0.01)
GI symptoms in 70.2% ASDs and no controls,
with a mild correlation by multivariate analyses
of constipation and alternating bowel versus
increased permeability to lactulose.
Was not indicated
whether the ASD
subjects had
intellectual disability
[43]
ASD w GI symptoms (n = 14)
Age 4–13 y
14 males
NT w GI symptoms (n = 15)
Age 3–18 y
12 males
3 females
NT w/o GI symptoms (n = 6)
Age 3–18 y
6 males
Sequencing of the 16S rRNA gene
(V1–V3 and V4 regions) on rectum
mucosal biopsy samples
Blautia ↓ (p = 0.02), Dorea ↓ (p = 0.006),
Sutterella ↓ (p = 0.025) in ASD w GI
symptoms vs. NT w GI symptoms
Clostridium lituseburense ↑ (p = 0.002),
Lachnoclostridium bolteae ↑ (p = 0.017),
Lachnoclostridium hathewayi ↑ (p = 0.03),
Clostridium aldenense ↑ (p = 0.03), and
Flavonifractor plautii ↑ (p = 0.03), in ASD
w GI symptoms vs. NT w GI symptoms
and NT w/o GI symptoms
Faecalibacterium prausnitzii ↑, Roseburia
intestinalis ↑, Oscillospira valericigenes ↑,
and Bilophila wadsworthia ↑ (p < 0.05) in
NT w GI symptoms vs. NT w/o GI
symptoms
IBS with ↑ Clostridium aldenense (p = 0.04);
Functional constipation with ↓ Flavonifractor
plautii (p = 0.03), Bacteroides eggerthii (p = 0.02),
Bacteroides uniformis (p = 0.04), Faecalibacterium
prausnitzii (p = 0.013), Clostridium clariflavum
(p = 0.03);
Aerophagia with ↑ Clostridium aldenense (p = 0.03),
↓ in Blautia luti (p = 0.003), Bifidobacterium
adolescentis (p = 0.01), Eubacterium ventriosum
(p = 0.05), Anoxystipes fissicatena (p = 0.02),
Coprococcus comes (p = 0.04), Eubacterium ramulus
(p = 0.006), and Phascolarctobacterium faecium
(p = 0.04);
Abdominal migraine with ↓ in Akkermansia
muciniphila (p = 0.03), Coprococcus catus (p = 0.007),
Odoribacter splanchnicus (p = 0.05), Clostridium
lactatifermentans (p = 0.03) and Ruminococcus
lactaris (p = 0.03)
Serotonin with Lachnoclostridium bolteae
(p = 0.002), Lachnoclostridium hathewayi (p = 0.003)
and Flavonifractor plautii (p = 0.001)
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
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Table 1. Cont.
Reference
Subjects Method Findings Limitations
Experimental Group Control Group Bacteria Correlation
[29]
ASD w GI symptoms (n = 33)
Age 2–9 y
Unidentified sex
HC w/o GI symptoms (n = 13)
Age 2–9 y
Unidentified sex
Selective culture methods for Clostridium
and for Clostridium perfringens strains on
fecal samples:
Brucella and CDC agar.
PCR for Clostridium perfringens toxin
genes: alpha (cpa), beta (cpb), beta 2
(cpb2), epsilon (ctx), iota (iA), and
enterotoxin (cpe)
Clostridium perfringens ↑ in ASD w GI
symptoms vs. HC (p = 0.03)
No correlations between GM and GI symptoms
were studies
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
[44]
ASD (n = 21) w GI symptoms
Age 14.4 ± 1.1 y
19 males
2 females
HC (n = 19) w GI symptoms
Age 16 ± 1.2 y
10 males
9 females
Pyrosequencing of the 16S rRNA gene
bacterial (V1–V3 regions) on duodenal
biopsies samples from the second part of
the duodenum
No differences in microbiome diversity
(alpha and beta)
Burkholderia ↑ (p = 0.03) and Neisseria ↓
(p = 0.01) in ASD vs. HC
Bacteroides vulgatus ↓ (p = 0.005),
unidentified Bacteroides ↓ (p = 0.04), and
Escherichia coli ↓ (p = 0.05) in ASD vs. HC
Oscillospira, Actinomyces,
Peptostreptococcus, and Ralstonia ↑
(p < 0.05) in ASD vs. HC
Devosia, Prevotella, Bacteroides, and
Streptococcus ↓ (p < 0.05) in ASD vs. HC
↑ frequency of constipation in ASD vs. HC
(p < 0.005)
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
[45]
ASD (n = 29) w GI symptoms
(49 isolated strains of
Clostridium perfringens)
Age 3.5–18 y
23 males
9 females
HC (n = 17) (30 isolated strains
of Clostridium perfringens)
Obese children (n = 24) (32
isolated strains of Clostridium
perfringens)
Unrevealed age and sex
Selective culture method for fecal
samples: Columbia blood and
reinforced clostridial agar under
anaerobic conditions. Hemolysis test,
lecithinase, and lipase production on
egg yolk agar, and identified with use of
ANC cards in VITEK 2 compact.
Subcultured in BHI broth and Gene
MATRIX DNA Purifi cation Kit by DNA
Gdansk for isolation of DN
Multiplex PCR for toxin alpha (cpa),
toxin beta (cbp), enterotoxin (ecpe),
iota-toxin (cpiA), epsilon toxin (etx)
genes
The cpa gene encoding alpha toxin was
present in all 111 (100%) strains
The cpb2 gene encoding beta2 toxin was
found in:
45/49 (91.8%) strains isolated from ASD
children, 17/30 (56.7%) strains isolated
from healthy subjects (p < 0.001), and
12/32 (37.5%) strains isolated from obese
children (p < 0.001)
Clostridium perfringens (cpb2 gene) was
detected in:
27/29 (93.1%) ASD,
10/17 (58.8%) HC (p < 0.008), and 11/24
(45.8%) obese children (p < 0.001)
No differences between HC and obese
children (cpb2 and Clostridium perfringens
with cpb2)
No correlations between GM and GI symptoms
were studies
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
A small number of
studied patients and
strains
[28]
ASD (n = 23) divided into ASD
w GI symptoms (21/23) and
ASD w/o GI symptoms (2/23)
Age 4–17 y
15 males
6 females
NT (n = 21) divided into NT w
GI symptoms (10/21) and NT
w/o GI symptoms (11/21)
Age 4–17 y
22 males
1 female
Pyrosequencing of the 16S rRNA gene
bacterial (V2–V3 regions) on fecal
samples
Gut microbial diversity (alpha) ↓
(p < 0.001) and relative abundances of
phylotypes most closely related to
Prevotella copri ↓ (p < 0.04) in ASD
Faecalibacterium ↓ (p < 0.01) and
Haemophilus ↓ (p < 0.05) in ASD vs. NT
Feacalibacterium prausnitzii ↓ (p < 0.01)
and Haemophilus parainfluenzae ↓
(p < 0.05) in ASD vs. NT
GI symptoms were significantly more severe for
children with ASD compared to controls (ATEC
subscale = p < 0.01)
ASD severity was not
indicated
Was not indicated
whether the ASD
subjects had
intellectual disability
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Table 1. Cont.
Reference
Subjects Method Findings Limitations
Experimental Group Control Group Bacteria Correlation
[46]
ASD (n = 30) divided into
severe ASD (28/30) and
moderate ASD (2/30) w GI
symptoms
Age 3–16 y
28 males
2 females
BMI 6.9–20.5
HC mostly Sib or blood
relatives to the ASD children
(n = 24) w/o GI symptoms
Age 3.5–16 y
15 males
9 females
BMI 13.4–31
Sequencing of the 16S rRNA gene
bacterial (V3 region) on fecal samples
Firmicutes ↑ in ASD vs. HC Sib (p < 0.05)
Prevotellaceae ↓ and Veillonelleaceae ↑ in
ASD vs. HC Sib
Lactobacillaceae ↑ (p = 0.018),
Bifidobacteriaceae ↑ (p = 0.0054), and
Veillonellaceae ↑ (p = 0.008) in ASD vs.
HC Sib
Erysipelotrichaceae ↑ (p = 0.0005),
Enterococcaceae ↑ (p = 0.0127), and
Desulfovibrionaceae ↑ (p = 0.03) in ASD vs.
HC Sib
Bifidobacterium ↑ (p = 0.005), Lactobacillus
↑ (p = 0.018), Megasphaera ↑ (p = 0.0008),
and Mirsuokella ↑ (p = 0.007) in ASD vs.
HC Sib
99% of Lactobacillus was Lactobacillus
ruminis in ASD group
No correlations between GM and GI symptoms
were studies
Was not indicated
whether the ASD
subjects had
intellectual disability
[47]
ASD w GI symptoms (blood:
n = 20, 15 males, 5 females)
(stool: n = 21, 17 males, 4
females)
ASD w/o GI symptoms (blood:
n = 26, 19 males, 7 females)
(stool: n = 29, 25 males, 4
females)
Age 3–12 y
HC w GI symptoms (blood:
n = 6, 5 males, 1 female)
(stool: n = 7, 6 males, 1 female)
HC w/o GI symptoms (blood:
n = 35, 24 males, 11 females)
(stool: n = 34, 32 males, 2
females)
Age 3–12 y
Sequencing of the 16S rRNA gene
bacterial (V3–V4 regions) on fecal
samples
Bacteroidaceae ↑, Lachnospiraceae ↑,
Ruminococcaceae ↑, and Prevotellaceae ↑ in
ASD w GI symptoms vs. HC w GI
symptoms
Il-5, IL-15, and IL-17 ↑ in ASD w GI
symptoms vs. ASD w/o GI symptoms
(after exposure to the TLR-4 agonist LPS)
TGFbeta1↓ in ASD w GI symptoms vs.
ASD w/o GI symptoms and HC w/o GI
symptoms (p < 0.05) (under the majority
of conditions examined)
Differences in the microbiome composition of
children with ASD vs HC groups, irrespective of
GI symptoms
ASD severity was not
indicated.
Was not indicated
whether the ASD
subjects had
intellectual disability
Limited sample size
and younger age of
the HC with GI
symptoms group
[48]
ASD w GI symptoms (n = 35,
29 males, 6 females)
Age 3–8 y
HC (n = 6, 5 males, 1 females)
Age 3–8 y
Sequencing of the 16S rRNA gene
bacterial (V3–V4 regions) on fecal
samples.
Firmicutes/Bacteroidetes ratio↑ in ASD w
GI symptoms vs. HC (p < 0.05)
Bacteroidetes ↑ in ASD w GI symptoms vs.
HC (p < 0.05)
Firmicutes ↓ in ASD w GI symptoms vs.
HC (p < 0.05)
Veillonella, Streptococcus, Escherichia,
Actinomyces, Parvimonas, Bulleida, and
Peptoniphilus ↓ in ASD w GI symptoms
vs. HC (p < 0.05)
Positive microbe-based link between periodontitis
and ASD
Negative microbe-based link between type 1
diabetes, constipation (p < 0.05), IBS, psoriasis,
and ASD
ASD severity was not
indicated.
Was not indicated
whether the ASD
subjects had
intellectual disability
A small number of
studied patients and
strains
Note: w = with; w/o = without; ASD = Autism Spectrum Disorder; HC = Healthy control; GI = Gastrointestinal; NT = Neurotypical; NT Sib = Neurotypical siblings; Sib = siblings;
y = years; ADI = Autism Diagnostic Interview; DHEA-S = dehydroepiandrosteronesulfate; IBS = Irritable Bowel Syndrome; BMI = Body Mass Index, FAA = Free Amino Acids; NT = HC;
ATEC = Autism Treatment Evaluation Checklist.
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Table 2. Review of author judgments on quality assessment for each included study.
Item [38] [39] [27] [40] [41] [31] [42] [30] [43] [29] [44] [45] [28] [46] [47] [48]
Clear stated aim 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Appropriate study size 1 2 2 1 2 1 2 2 1 1 2 2 2 2 1 1
Identified and assessed 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Comparability 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Blinding of participants and personnel 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Other bias (dietary intake controlled, reports
on comorbidity and severity of ASD) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Adequate statistical analyses 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
TOTAL 9 10 10 9 9 9 10 10 9 9 10 10 10 10 9 9
Risk of bias 5 4 4 5 5 5 4 4 5 5 4 4 4 4 5 5
Overall risk of bias M M M M M M M M M M M M M M M M
0 = Not reported, 1 = not adequately assessed, 2 = adequately assessed; M = Medium (8–10); L = Low (9–14);
H = High (7–1).
3. Results
Table 1 shows the sixteen studies included in the present systematic review and the results of the
analysis of the samples in children with ASD and GI symptoms.
3.1. Assessment of Risk of Bias for Each Included Article
The 16 articles were identified and assessed as medium to high quality (Table 2). When assessing
the quality of selection, the studies presented some limitations in terms of sample size, information on
comorbidity of neurodevelopmental disorders, diet of study participants, blinding of participants and
personnel, and mean scores and standard deviations in the analysis of study data. Many of these studies
were also open-label trials and relied on qualitative, self-reported questionnaires and surveys to gauge
treatment response, inviting potential bias into the studies. There might also be various difficulties
experienced by the parents in evaluating these aspects, especially owing to the communication deficits
typical of children with ASD. More randomized, controlled studies with a larger study population and
the use of clinician scoring may lead to more robust studies and results [17].
3.2. Relationship between GI Symptoms and ASD
Among the 16 articles found in the present systematic review, ten of them performed analysis
to try to find correlations between GI symptoms and ASD. Seven articles found statistically
significant differences between the occurrence of GI symptoms in children with ASD and healthy
controls [28,30,31,42–44,48], and three articles found no such differences [27,39,41]. The remaining
six articles did not perform statistical analysis to analyze correlations between GI symptoms and
ASD [29,38,40,45–47].
The most common GI symptom in children with ASD was found to be constipation, results in
line with those reported elsewhere [10]. In this sense, five articles reported statistically significant
differences in children with ASD suffering constipation compared to healthy controls [30,42–44,48].
3.3. Relationship between Gut Microbe Abundance and GI Symptoms in Children with ASD
Three articles tried to find correlations between the GI symptoms of children with ASD and
gut microbe abundance [31,42,43]. Two of those articles found correlations between certain gut
microbes and GI symptoms, specifically constipation [42,43], and irritable bowel syndrome, functional
constipation, aerophagia, and abdominal migraine [43]. In light of those results, some genera of
bacteria are involved in constipation, but the results between the studies are not coincident (Table 1).
The remain article reported no correlation between Desulfovibrio and GI symptoms [31].
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3.4. Gut Microbiota Dysbiosis found in children with ASD and GI Symptoms
Seven articles reported statistically significant differences in the presence of GI symptoms in
children with ASD compared to healthy controls [28,30,31,42–44,48]. These articles also showed
significant differences in the abundance of some gut microbes in children with ASD suffering GI
symptoms (Table 1) compared to their respective control groups. The gut microbes that were found by
more than one article to show significant differences in abundance are listed below.
Candida was found to be the only gut microbe that showed significantly higher abundance in
children with ASD and GI symptoms compared to their control groups by more than one article [30,42].
Lower abundance of Prevotella [27,44], Veillonella [42,48], and Streptococcus [44,48] in children with
ASD and GI symptoms compared to their control groups was also found to be statistically significant.
In addition, some gut microbes showed discrepancies at a statistically significant level regarding
their abundance in children with ASD and GI symptoms compared to their control groups. Specifically,
at phylum level, Bacteroidetes [42,48] and Firmicutes [31,48]; at genus level, Actinomyces [44,48],
Dorea [42,43], and Lactobacillus [30,31,42]; and at species level, Faecalibacterium prausnitzii [28,43].
The Bacteroidetes/Firmicutes ratio also showed discrepancies at a statistically significant level regarding
their abundance in children with ASD and GI symptoms compared to their control groups [31,42,48].
3.5. Limitations
An important limitation of the studies is the absence of a psychometric analysis of the relationship
between the severity of behavioral ASD symptoms with GM abundance and GI symptoms. Similarly,
none of the studies indicated whether children with ASD presented a diagnosis of intellectual disability,
although cognitive difficulties are a determining factor in the severity of ASD symptoms [49].
On the other hand, the present systematic review has the same limitations as other systematic
reviews, such as the databases used, the established inclusion/exclusion criteria, database selection,
keywords, or time-frame chosen. In addition, the lack of sufficient articles made it impossible to
combine the results into a meta-analysis [9].
4. Discussion
The present systematic review found 16 articles that studied the GM in children with ASD and
GI symptoms, and, as discussed before, among the 10 articles that analyzed the correlation between
GI symptoms and ASD, 7 of them found significant differences. These results are similar to those
reported by Adams et al. [50], who found a strong correlation between the 6-GSI score and the Autism
Treatment Evaluation Checklist score (Pearson’s correlation coefficient r = 0.60; p < 0.001). Those
results are also in line with a meta-analysis which included 15 articles comparing heterogeneous
groups (siblings, ASD and healthy control) [9]. Among the 15 selected articles, 10, 12, 9, and 8 reported
general GI concerns (p < 0.0001), diarrhea (p < 0.0001), constipation (p < 0.0001), and abdominal pain
(p = 0.016), respectively. In conclusion, there seems to be evidence that there is a greater prevalence of
GI symptoms among children with ASD compared with control children.
On the other hand, three studies [31,42,43] analyzed the correlation between gut microbe
abundance and GI symptoms in children with ASD and GI symptoms. Although the studies are very
promising, there is not yet enough scientific evidence to determine the relationships between gut
microbe abundance and GI symptoms in children with ASD, as the gut microbes found to be correlated
with GI symptoms in children with ASD were different between the different studies (Table 1). In this
sense, the results are very premature, and the number of articles found was very low. Therefore,
as discussed before, it was not possible to perform a meta-analysis of the relationships between gut
microbes and GI symptoms in children with ASD [9].
Regarding the abundance of some gut microbes in children with ASD and GI symptoms, Candida
was found to be more abundant by two studies [30,42], Candida albicans being the most frequently
identified species [30]. In fact, it has been reported that a high abundance of Candida albicans can cause
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lower absorption of carbohydrates and minerals, and can generate higher toxins levels in the GI tract
that can contribute to some ASD behaviors [51]. It has been also reported that the immunological
responses to Candida in the GI tract can be modulated by some Lactobacillus species [42,52]. In this
sense, it is possible that a dysbiotic GM in ASD may lead to a Candida population expansion, as can be
observed by the lower abundance of Lactobacillus found in Italian children with ASD and GI symptoms
compared to their control group [30]. However, a higher abundance of both Lactobacillus and Candida
was also found in Italian children with ASD and GI symptoms compared to their control group [42].
Therefore, these results are not conclusive, and, as can be observed, there is a clear lack of investigation
of the whole Fungi kingdom in children with ASD, and little is still known about the role of Candida
and other types of fungi in both GI and ASD symptoms [34].
Lower abundances of three gut microbe genera (Prevotella [27,44], Veillonella [42,48],
and Streptococcus [44,48]) in children with ASD and GI symptoms were also reported by more
than one article included in the present systematic review. Lower abundance of Prevotella may act as an
indicator of Westernization, and this fact can also result in an altered immune system [53]. In addition,
the presence of Prevotella together with other Bacteroidetes is also associated with colon health, and
it has been hypothesized that ASD can be triggered by a dysbiosis where Prevotella decreases and
Sutterella increases [54]. In this sense, the lower abundance of Prevotella found in American children
with ASD was associated with the presence of ASD symptoms instead of GI symptoms [27]. These
authors did not find this association in a later work [28], although they found that GI symptoms were
significantly more severe in children with ASD compared to their control group.
Streptococcus, together with Lactobacillus, Bifidobacterium, and Lactococcus, are lactate producing
bacteria [48]. It is known that children with ASD show elevated levels of both lactate and GI
symptoms [55], suggesting an elevation of glycolysis through the phenomenon of aerobic glycolysis in
ASD, since the dysregulation of this balance has been also been proposed as a trigger for ASD [56].
In this sense, as Veillonella is also able to ferment lactate, a lower abundance of Veillonella may also
disturb the fermentation of lactate in children with ASD [48]. However, it cannot be stated that the
elevated levels of lactate in people with ASD and GI symptoms can be attributed only to the GM,
since, as discussed before, there are discrepancies in the abundance of other lactate-producing bacteria,
such as Lactobacillus. Regarding the implications of Veillonella in GI symptoms presented by children
with ASD, Veillonellaceae, together with Prevotellaceae, Prevotella, and Coprococcus, has been included
in a probiotic mixture for treating ASD [57], and it is known that the differences in GM composition
(especially in Veillonella) of children with ASD may be a consequence of diet [27,46].
The discrepancies found, at a statistically significant level, in the abundance of Bacteroidetes [42,48]
and Firmicutes [31,48] phyla; Actinomyces [44,48], Dorea [42,43], and Lactobacillus [30,31,42] genera;
Faecalibacterium prausnitzii species 28,43]; and Bacteroidetes/Firmicutes ratio [31,42,48] can be explained
by several factors such as ASD heterology, age of participants, nature of control groups, sample
location, small sample sizes, different nationalities, inter-individual differences, or different bacterial
identification methods [14,31,53,58]. For example, one study used a culture-dependent method to
detect Lactobacillus [30], and it was found to be less abundant in children with ASD and GI symptoms
compared to the control group. However, two studies [31,42] that used culture-independent methods
found opposite results, and although some authors have postulated that both methods yield similar
results [59], culture-independent methods are relatively new and they are still developing [26]. Another
study found a higher abundance of Dorea in stool samples of children with ASD and GI symptoms [42],
while other studies found opposite results taken from rectum mucosal biopsy samples, and it is known
that the place where the sample is taken can be relevant for mammalian physiology [14], as there
are differences in microbial composition between stool and the GM [60,61]. This was confirmed in a
larger-scale study showing that the populations recovered in the stool seemed to combine bacteria
derived from the mucous membrane and the luminal part of the intestine, either adherent or not
adherent to transient organic matter [62]. It is assumed that microorganisms seen in the stool reflect
the microbiology of the colon, particularly the descending colon and rectum. Finally, it is important
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to highlight that there are still existing gaps in knowledge regarding the interactions between the
microbiome and the host in vivo—and the pathways of metabolites—and how their metabolites
influence the microenvironment. Therefore, further mechanistic studies involving "omics" technologies,
as adapted from previous studies [63], might help shed light on these questions, and future studies
should try to homogenize, as much as possible, the characteristics of the samples to be compared,
including the place where the sample is taken from and bacterial detection methods, among others.
5. Conclusions
Although recent scientific literature has provided evidence of the relationship between GI
symptoms and ASD, it is still too early to draw a conclusion about the gut microbes involved in GI
symptoms of children with ASD, due to the limited number of studies reporting correlations between
them. Furthermore, the correlation between certain gut microbes and GI problems do not determine
the causality of the symptoms. However, it can be said that children with ASD and GI symptoms show
higher abundance of Candida, lower abundance of Prevotella, Veillonella, and Streptococcus, and also
show discrepancies in the abundance of other gut microbes due to ASD heterology, age of participants,
nature of control groups, sample location, small sample sizes, different nationalities, inter-individual
differences, or different bacterial identification methods. In addition, we consider that ASD has a wide
phenotypic variability, so future studies should consider the relationship between GM, GI symptoms,
and behavior of ASD in a more integral and multidisciplinary way. Finally, we argue that future
research should homogenize sample characterization in order to develop a meta-analysis on the GM
involved in ASD children with GI symptoms.
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